<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02133079</url>
  </required_header>
  <id_info>
    <org_study_id>CS-CIH-Li-01</org_study_id>
    <nct_id>NCT02133079</nct_id>
  </id_info>
  <brief_title>Immunotherapy of Tumor With Autologous Tumor Derived Heat Shock Protein gp96</brief_title>
  <official_title>Immunotherapy of Tumor With Autologous Tumor Derived Heat Shock Protein gp96</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cure&amp;Sure Biotech Co., LTD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cure&amp;Sure Biotech Co., LTD</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and effectiveness of autologous gp96 treatment of liver cancer and
      Pancreatic Adenocarcinoma
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>blood count</measure>
    <time_frame>baseline</time_frame>
    <description>blood count within 3 days before first vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>blood count</measure>
    <time_frame>within 3 days after the second injection</time_frame>
    <description>blood count within 3 days after the second injection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>blood count</measure>
    <time_frame>within 3 days after the 6th injection</time_frame>
    <description>blood count within 3 days after the 6th injection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>blood chemistries</measure>
    <time_frame>baseline</time_frame>
    <description>blood chemistries (including serum glutamic oxaloacetic transaminase/ aspartate aminotransferase [AST], serum alanine amino transferase [ALT], serum alkaline phosphatase, serum total bilirubin, serum blood urea nitrogen[BUN], serum creatinine, serum total protein and serum albumin) within 3 days before first vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>blood chemistries</measure>
    <time_frame>within 3 days after the second injection</time_frame>
    <description>blood chemistries (including serum glutamic oxaloacetic transaminase/ aspartate aminotransferase [AST], serum alanine amino transferase [ALT], serum alkaline phosphatase, serum total bilirubin, serum blood urea nitrogen[BUN], serum creatinine, serum total protein and serum albumin) within 3 days after the second injection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>blood chemistries</measure>
    <time_frame>within 3 days after the 6th injection</time_frame>
    <description>blood chemistries (including serum glutamic oxaloacetic transaminase/ aspartate aminotransferase [AST], serum alanine amino transferase [ALT], serum alkaline phosphatase, serum total bilirubin, serum blood urea nitrogen[BUN], serum creatinine, serum total protein and serum albumin) within 3 days after the 6th injection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>electrocardiogram</measure>
    <time_frame>baseline</time_frame>
    <description>electrocardiogram test within 3 days before first vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>electrocardiogram</measure>
    <time_frame>within 3 days after the second injection</time_frame>
    <description>electrocardiogram test within 3 days after the second injection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>electrocardiogram</measure>
    <time_frame>within 3 days after the 6th injection</time_frame>
    <description>electrocardiogram test within 3 days after the 6th injection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survive</measure>
    <time_frame>up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in antigen specific T cells</measure>
    <time_frame>baseline and within 3 days before the 6th injection</time_frame>
    <description>tumor antigen specific T cells was determined by IFN-γ Enzyme-linked immunosorbent spot using the autologous tumor cell lysis as the antigen.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline in subpopulation of CD8+ T cells at the end of vaccination</measure>
    <time_frame>within 3 days before the first vaccination, within 3 days after the 6th vaccination</time_frame>
    <description>analysis of the expression of CCR7 &amp; CD45RA of CD8+ T cells by FCM within 3 days before first vaccination and within 3 days after the 6th vaccination.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Liver Cancer</condition>
  <condition>Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>gp96 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>autologous gp96 vaccination + basal treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous gp96 vaccination</intervention_name>
    <description>vaccination of autologous gp96 derived from tumor tissue + basal treatment</description>
    <arm_group_label>gp96 group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Able to read and understand the informed consent document; must sign the informed
             consent;

          2. Aged 18 to 75 years old , sex is not limited;

          3. Pancreatic cancer or primary liver cancer,must have undergone radical resection;

          4. Availability of at least 0.5 g tumor sample;

          5. Receiving the first gp96 autologous immunotherapy within 8 weeks of postoperation;

          6. Patients could not have received previous chemotherapy, radiation, or immunotherapy
             before 4 weeks of gp96 treatment；

          7. ECOG ≤1；life expectancy of at least 12 weeks

          8. Adequate bone marrow function including the absence of lymphopenia (ANC &gt; 1,500/ mm3;
             Hemoglobin &gt; 10g/dL ; platelet count &gt;100,000/mm3), adequate liver function (serum
             glutamic oxaloacetic transaminase/ aspartate aminotransferase [AST], alanine amino
             transferase [ALT] &lt;2.5 times institutional upper limit of normals [IULNs] and
             bilirubin (total) &lt;1.5 times IULN), and adequate renal function (BUN and creatinine
             &lt;1.5 times IULNs); 9. Agree to Surgical indications of Heart &amp; lung and without the
             coagulation system disease;

        10.Negative pregnancy test for female patients of childbearing potential; 11.Agree to use
        contraception or abstain from sexual activity from the time of consent through 3 month
        after the end of study drug administration.

        Exclusion Criteria:

          1. Unable to get the informed consent ;

          2. Patient not suitable for radical resection;

          3. Patients with active liver disease；

          4. Did not get enough tumor tissue ;

          5. Progression prior to vaccination as determined by the Principal Investigator;

          6. Rreceiving other anti-cancer therapy at the same time;

          7. Patient with allergic constitution;

          8. Unstable or severe intercurrent medical conditions;

          9. Current diagnosis of Human Immunodeficiency Virus and Patients with active
             uncontrolled infection;

         10. Patients with any systemic disease needed to be treated with immunosuppressant or
             Corticosteroids;

         11. Any other cilical trials within 30 days pre-vaccination;

         12. Female patients who are pregnant or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianqiang Cai, meidical</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Insititute and Hospital,Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lei Yu, medical</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Insititute and Hospital,Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Insititute and Hospital,Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2014</study_first_submitted>
  <study_first_submitted_qc>May 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2014</study_first_posted>
  <last_update_submitted>December 10, 2015</last_update_submitted>
  <last_update_submitted_qc>December 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

